Andrew Muddle

Andrew Muddle is an advisor for the Buccal-PEP project, which is developing a multifunctional biomaterial patch for buccal (in-cheek) delivery of peptide-analogue therapies.13 He is the founder and former CEO of MedPharm, a company specializing in transdermal and topical products.3

Muddle's expertise lies in managing projects through to commercialization, with a particular focus on transdermal and topical products.3 His involvement in the Buccal-PEP project is significant, as he brings valuable experience in drug delivery systems and product development.

As a member of the Scientific Advisory Board for Buccal-PEP, Muddle contributes his knowledge and insights to guide the project's development.4 He has expressed pride in his role as an advisor and looks forward to collaborating with the team.2

The Buccal-PEP project aims to overcome challenges in peptide-analogue therapies by developing a novel delivery system that integrates a permeation enhancer with biomaterials and peptide-analogues.1 This innovative approach has the potential to improve patient quality of life and increase treatment compliance for conditions such as Type 2 Diabetes, which is being used as a showcase indication for the technology.1